Medicine and Dentistry
Radiation Therapy
100%
Neoplasm
43%
Malignant Neoplasm
33%
Overall Survival
29%
Prostate Cancer
23%
Diseases
21%
Celiac Plexus
21%
Clinical Trial
21%
Pancreas Cancer
20%
Radiosurgery
20%
Glioblastoma
19%
Stereotactic Body Radiation Therapy
19%
Non Small Cell Lung Cancer
17%
Chemoradiotherapy
17%
Ganglioglioma
16%
Lung Cancer
16%
Continuous Positive Airway Pressure
16%
Epidermal Growth Factor Receptor
12%
Metastatic Carcinoma
12%
Lung
12%
Biochemical Recurrence
11%
Breast Cancer
11%
Computer Assisted Tomography
11%
Elderly Patient
10%
Lymph Node
10%
Adjuvant Chemotherapy
10%
Radiation Oncology
10%
Temozolomide
9%
Re-Irradiation
9%
Intensity Modulated Radiation Therapy
9%
Radiosensitivity
9%
Cancer Cell
9%
Long Term Survival
9%
Pancreas Adenocarcinoma
8%
Prostate Specific Antigen
8%
Stomach Adenocarcinoma
8%
Hazard Ratio
8%
Symptomatic Treatment
8%
Androgen Deprivation Therapy
8%
Recurrent Disease
8%
Progression Free Survival
8%
Analgesia
8%
Brain Metastasis
7%
Breathing
7%
Cancer
7%
Hypofractionated Radiotherapy
7%
Radiosensitizer
7%
Immunotherapy
7%
Phase I Trials
6%
Proportional Hazards Model
6%
Keyphrases
Radiation Therapy
60%
Radiotherapy
41%
Overall Survival
28%
Radiosurgery
20%
Celiac Plexus
18%
Tumor
17%
Glioblastoma
16%
Continuous Positive Airway Pressure
16%
Radiosensitization
16%
Pancreatic Cancer
15%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
15%
High-grade Glioma
15%
Prostate Cancer
14%
Chemotherapy
12%
Clinical Outcomes
12%
Long-term Survival
12%
Androgen Deprivation Therapy
12%
Local Control
11%
Prostate-specific Antigen
11%
Biochemical Failure
11%
Cancer Patients
11%
Temozolomide
11%
Prostate
11%
Hazard Ratio
10%
Lung
10%
Adjuvant Chemotherapy
10%
Elderly Patients
10%
Re-irradiation
9%
Confidence Interval
9%
Israel
9%
Neoadjuvant Chemoradiotherapy (nCRT)
9%
Non-small Cell Lung Cancer Patients
9%
Progression-free Survival
8%
Stereotactic Body Radiotherapy
8%
Radiation Oncology
8%
Phase I Trial
8%
Multivariate Analysis
8%
Brain Metastases
8%
Prostate Cancer Patients
8%
Metastatic Colorectal Cancer (mCRC)
7%
Lung Cancer
7%
Pain Management
7%
Radiation Treatment Planning
7%
Ionizing Radiation
7%
Dose Escalation
7%
Single Fraction
7%
Pathological Stage
7%
Non-small Cell Lung Cancer (NSCLC)
7%
Locally Advanced
7%
Drug Combination
7%